Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sialic acid residues are nine-carbon monosaccharides, primarily N-acetylneuraminic acid (Neu5Ac), attached as terminal components to glycoproteins, glycolipids, and proteoglycans on cell surfaces, forming the glycocalyx. They are added via α2,3-, α2,6-, or α2,8-linkages by Golgi sialyltransferases using CMP-Neu5Ac, conferring negative charge, hydrophilicity, and bulkiness that mediate anti-adhesive properties, self-recognition (e.g., by Siglecs and Factor H), leukocyte rolling via sialyl-Lewis X, and protection from clearance or degradation. Removal occurs by sialidases in endosomes, lysosomes, or at the plasma membrane. While not a discrete receptor or protein target, these residues are functional elements influencing pathophysiology, but no approved drugs directly target them as a canonical therapeutic entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sialic acid residues on glycoconjugates.